Hidradenitis Suppurativa in the Pediatric Population

An OMNY Health™ Poster

Givent the limited literature, it is important to understand current characteristics and treatments of pediatric patients with hidradenitis suppurativa (HS).

On May 15 – May 18, 2022, this poster was on display at ISPOR 2022.


  • Results provide insight into characteristics and treatments of pediatric HS within a diverse set of US healthcare setting.
  • Acne presented as the most common comorbidity while TC and SAI were the most common forms of treatment prescribed to patients.
  • Future analyses would be helpful to determine patient journeys and burden of disease among pediatric HS patients.


Check Out More Events & Webinars…


By continuing to use the site, you agree to the use of cookies. More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below, then you are consenting to this.